785774-34-7
Chemical Structure
SB772077B
- CAS No.: 785774-34-7
- Formula:C15H18N8O2
- Molecular Weight:342.36
IUPAC Name: (S)-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl)(3-aminopyrrolidin-1-yl)methanone
InChIKey: PHWHNHYZZNJPLB-QMMMGPOBSA-N
SMILES: NC1=NON=C1C(N2CC)=NC3=C2C(C(N4C[C@@H](N)CC4)=O)=CN=C3
Biological Activity: SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB772077B | SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ashwinbalaji S, et al. SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes. Sci Rep. 2018 Oct 19;8(1):15472. [Content Brief]
- [2]. Dhaliwal J S, et al. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl) carbonyl)-1-ethyl-1H-imidazo (4, 5-c) pyridin-2-yl)-1, 2, 5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor[J]. The Journal of pharmacology and experimental therapeutics, 2009, 330(1): 334-341.
Keywords
